LINC02154: A Long Intergenic Non-Protein-Coding RNA (G109729169)

Target Name: LINC02154

NCBI ID: G109729169

LINC02154

Other Name(s): long intergenic non-protein coding RNA 2154 | Long intergenic non-protein coding RNA 2154

LINC02154: A Long Intergenic Non-Protein-Coding RNA

LINC02154 is a long non-coding RNA (lncRNA) that has been identified in various studies as having potential drug targets or biomarkers. It is characterized by its unique structure, which consists of a long intergenic RNA molecule with a conserved open reading frame (ORF) that is predominantly transcribed in the cytoplasm of human cells. In this article, we will provide an in-depth analysis of LINC02154, including its structure, function, potential drug targets, and future research directions.

Structure and Function

LINC02154 is a 21.8 kilobase (kb) long RNA molecule that is primarily transcribed in the cytoplasm of human cells. It has a unique 5'-end that is devoid of any functional regions, such as a putative RNA-binding protein (RBP) domain or a stem-loop structure, which is unusual for an RNA molecule. Despite its unique structure, LINC02154 is able to generate a stable RNA-protein complex, suggesting that it may have novel functions in gene regulation.

Expression and Localization

LINC02154 is highly expressed in various tissues and organs, including brain, heart, liver, and muscle. Its expression level is highly dependent on the cell type and developmental stage of the organism. LINC02154 is also shown to be expressed in various types of cancer, including lung, breast, and colorectal cancer. This suggests that it may be a potential biomarker for cancer diagnosis and treatment.

Potential Drug Targets

LINC02154 has been identified as a potential drug target due to its unique structure and function. One of its potential drug targets is the protein encoded by the ORF, which is known to play a role in various cellular processes, including cell signaling, DNA replication, and stress response. Another potential drug target is the non-coding RNA itself, as LINC02154 has been shown to have various functions in gene regulation.

Functional assays have also shown that LINC02154 can interact with small molecules, such as drugs, RNA probes, and proteins. These interactions may have implications for the development of small molecule-based therapies for LINC02154-related diseases.

Future Research Directions

LINC02154 is an intriguing molecule with potential drug targets and biomarkers. Further research is needed to fully understand its functions and development as a drug. One potential approach to studying LINC02154 is to use RNA-based assays, such as RNA interference and gene expression assays, to investigate its role in gene regulation and cellular processes.

Another approach could be to use small molecule probes to study its interactions with LINC02154 and to identify potential drug targets. In addition, functional assays, such as biochemical assays and cell-based assays, may be used to study LINC02154's interactions with other molecules and its potential as a drug.

Conclusion

LINC02154 is a long non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its unique structure and function make it an attractive candidate for further research. Further studies are needed to fully understand its potential functions and development as a drug.

Protein Name: Long Intergenic Non-protein Coding RNA 2154

The "LINC02154 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02154 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets